Lantheus Holdings has agreed to sell its contract development and manufacturing business and its Springfield, New Jersey, manufacturing facility to PharmaLogic Holdings. The deal also includes a long-term supply arrangement under which PharmaLogic’s Agilera therapeutic manufacturing business will make lutetium Lu 177 dotatate for Lantheus.
- The sale is subject to customary closing conditions. Lantheus will provide transition services to PharmaLogic immediately after the transaction closes.
- Under the planned long-term supply agreement, Agilera will manufacture lutetium Lu 177 dotatate, a product Lantheus will continue to obtain from PharmaLogic after the sale.
- Lantheus did not provide a purchase price or an expected closing date.
The transaction would transfer Lantheus’s CDMO business and Springfield facility to PharmaLogic while establishing PharmaLogic as a long-term manufacturer of lutetium Lu 177 dotatate for Lantheus.